NTRK1 and neoplasm: Angiogenic inhibitors (such as VEGFR2-specific antibody and sunitinib—an oral, small-molecule, multitargeted receptor tyrosine kinase inhibitor) targeting the VEGF pathway have been shown to display anti-tumor effects in mouse models of pancreatic neuroendocrine carcinoma and glioblastoma but concomitantly induced tumor progression to greater malignancy with adaptive “evasive resistance” [183].